Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — 40th Annual EAU Congress (EAU25) (March 2025)
14 slides from Cg Oncology's conference presentation, Mar 24, 2025
Slide 1: Updated Clinical & Translational Results: BOND-003 Cohort C
Updated Clinical & Translational Results: For individual reference only. The information accessed through this QR code is intended solely for individual BOND-003 Cohort C- A Phase 3, Single-Arm reference and should not be altered, modified, or reproduced in any way. Study of Intravesical Cretostimog
Slide 2: Disclosures
Disclosures ‣ CG Oncology- Clinical Investigator & Scientific Advisory Board 2
Slide 3: What is Cretostimogene Grenadenorepvec?
What is Cretostimogene Grenadenorepvec? ‣ Oncolytic immunotherapy with dual MOA Cretostimogene in Cancer Cells o Viral replication results in tumor lysis P P Rb or Rb Viral o Stimulation of immune response P P Replication Cretostimogene E2F replicates in and lyses cancer cells ‣ Conditionally replic
Slide 4: Phase 3 Cretostimogene Monotherapy for High-Risk BCG-Unresponsive NMIBC with CIS
Phase 3 Cretostimogene Monotherapy for High-Risk BCG-Unresponsive NMIBC with CIS HR BCG-Unresponsive NMIBC Cretostimogene Grenadenorepvec Primary Endpoint: Single-Arm, Open-Label, IVE Administration CR at Any Time Population Study Design / Regimen Additional Endpoints ‣ Enrollment complete (n=112) I
Slide 5: Patient Demographics & Baseline Characteristics
Patient Demographics & Baseline Characteristics Subjects in Safety Dataset N=112 % Gender Male 83 74.1 Female 29 25.9 Age (Years) ‣ Majority of patients are: Mean (SD) 72.9 (9.19) o Male (74%) Median (Range) 74.0 (43-90) o White (62%) Age (Categories) < 65 19 17.0 o > 65 years (83%) ≥ 65 and < 75 43
Slide 6: Consistent and Compelling CR & Durability Data
Consistent and Compelling CR & Durability Data Overall Complete Response 100 75.5% CR Landmark CR Rate, % (95% CI) CR by K-M Est, % (95% CI) (95% CI, 66.3 % - 83.2 %) 46% (36.9, 56.1)1 Overall CR Rate (%) 75 12-month 51 out of 110 patients 50% (39.6, 58.9) 30 Confirmed CRs 24-month that have reached
Slide 7: Cretostimogene Demonstrates Sustained and Ongoing Duration of Response in HR BCG-UR NMIBC
Cretostimogene Demonstrates Sustained and Ongoing Duration of Response in HR BCG-UR NMIBC Estimated DOR Probability at 12 Months Estimated DOR Probability at Duration of Response Probability (%) 63.7% 24 Months (95% CI: 51.8-73.3) 58.7% (95% CI: 46.4-69.0) ‣ Median DoR exceeds 28 months (95% CI 14.3
Slide 8: Favorable & Well-Tolerated Safety Profile
Favorable & Well-Tolerated Safety Profile Cretostimogene (n=112) Preferred Term (MedDRA v.26.1) Any Grade (%) Grade ≥ 3 ‣ Most AEs were Grade 1-2 Patients with ≥ 1 TRAE 72 (64.3%) 0 (0) ‣ 0% Grade ≥ 3 TRAEs or deaths Treatment-Related AE reported in > 10% patients ‣ 1-day median time to TRAE resolut
Slide 9: Viral Replication and Transgene Expression (Induction)
Viral Replication and Transgene Expression (Induction) Pre-admin Creto Titer Pre-admin GM-CSF (qPCR in urine) (Olink Target 48 in urine) ‣ Cretostimogene replication Post-admin Creto Titer Post-admin GM-CSF 108 (qPCR in urine) (Olink Target 48 in urine) 107 and GM-CSF expression are linked Cretostim
Slide 10: Viral Replication and Transgene Expression (Maintenance)
Viral Replication and Transgene Expression (Maintenance) Pre-admin Creto Titer Pre-admin GM-CSF (qPCR in urine) (Olink Target 48 in urine) Post-admin Creto Titer Post-admin GM-CSF (qPCR in urine) (Olink Target 48 in urine) ‣ Similar pharmacokinetic Cretostimogene Titer in Urine peak and trough patte
Slide 11: Robust and Stable Immune Activity
Robust and Stable Immune Activity Cretostimogene Titer ‣ Pre-existing Ad5 antibodies (qPCR in urine) 109 106 Ad5 ADA (Immunoassay in serum) ‣ Immune priming 108 Cretostimogene Titer in Urine ‣ Stable antibody and anti- 107 (Genome Copy Number/mL) Ad5 ADA Titer in Serum 106 105 tumor response over ti
Slide 12: No Systemic Shedding
No Systemic Shedding Geometric Mean (copies/mL) ‣ No systemic exposure ‣ Creto levels remain below the limit of detection ‣ Concentrated within the bladder, even with repeat dosing Week BLOD = Below Limit of Detection (< 290 copies/mL); BLOQ= Below Limit of Quantification (< 1741 copies/mL) 12
Slide 13: Key Takeaways
Key Takeaways ‣ Oncolytic immunotherapy with dual MOA ‣ Highly effective, very well tolerated regimen ‣ Translational analyses validate sustained local activity, dose, treatment schedule, and legacy data ‣ No post-cretostimogene close contact precautions ‣ Final BOND-003 Cohort C results to be prese
Slide 14: Thank You
For individual reference only. The information accessed through this QR code is intended solely for individual reference and should not be altered, modified, or reproduced in any way. Thank You All Bladder Cancer Patients and Their Families Key Investigators, Study Coordinators, Nurses
CG Oncology — 40th Annual EAU Congress (EAU25) (March 2025) on 6ix